Atigotatug

Atigotatug (BMS-986489) is a monoclonal antibody developed by Bristol-Myers Squibb. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: Atigotatug is an anti-fucosyl-GM1 antibody supplied as a fixed-dose combination with the PD-1 inhibitor nivolumab. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06646276 (A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)), in non-small-cell lung cancer. The largest, NCT06646276, plans to enrol 530 participants with primary completion expected 2028-04-06. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.